Venrock Healthcare Capital Par Purchases 100,000 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par purchased 100,000 shares of the firm’s stock in a transaction dated Wednesday, February 12th. The shares were purchased at an average cost of $9.23 per share, for a total transaction of $923,000.00. Following the purchase, the insider now directly owns 5,217,285 shares in the company, valued at approximately $48,155,540.55. This represents a 1.95 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $9.14 per share, for a total transaction of $37,812.18.
• On Friday, February 7th, Venrock Healthcare Capital Par acquired 73,649 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $9.29 per share, for a total transaction of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average price of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Stock Performance

KALV opened at $9.76 on Monday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $16.88. The company’s 50 day simple moving average is $8.75 and its 200 day simple moving average is $10.48. The stock has a market capitalization of $482.34 million, a PE ratio of -2.68 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. As a group, sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 73.9% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after purchasing an additional 1,700,000 shares during the period. Boxer Capital Management LLC acquired a new stake in KalVista Pharmaceuticals during the 4th quarter worth approximately $13,467,000. State Street Corp raised its holdings in KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after buying an additional 515,179 shares during the period. Schroder Investment Management Group lifted its position in KalVista Pharmaceuticals by 86.8% during the fourth quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company’s stock valued at $6,758,000 after buying an additional 374,213 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in KalVista Pharmaceuticals during the fourth quarter worth approximately $2,268,000.

Analyst Upgrades and Downgrades

KALV has been the topic of a number of analyst reports. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Finally, Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).